Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 3/1998

01-04-1998

Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis

Authors: Richard E. B. Seftor, Elisabeth A. Seftor, Joseph E. De Larco, David E. Kleiner, Jill Leferson, William G. Stetler-Stevenson, Thomas F. McNamara, Lorne M. Golub, Mary J. C. Hendrix

Published in: Clinical & Experimental Metastasis | Issue 3/1998

Login to get access
Metadata
Title
Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
Authors
Richard E. B. Seftor
Elisabeth A. Seftor
Joseph E. De Larco
David E. Kleiner
Jill Leferson
William G. Stetler-Stevenson
Thomas F. McNamara
Lorne M. Golub
Mary J. C. Hendrix
Publication date
01-04-1998
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 3/1998
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006588708131

Other articles of this Issue 3/1998

Clinical & Experimental Metastasis 3/1998 Go to the issue

OriginalPaper

The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells

OriginalPaper

Thymosin β15 expression in tumor cell lines with varying metastatic potential

OriginalPaper

Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells

OriginalPaper

Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels

OriginalPaper

Enhancement of type IV collagenases by highly metastatic variants of HT1080 fibrosarcoma cells established by a transendothelial invasion system in vitro

OriginalPaper

C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits